Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00908336
Show Display Options
Rank Status Study
1 Unknown  Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Docetaxel and Erlotinib;   Drug: Erlotinib

Indicates status has not been verified in more than two years